HTD2

Across TCGA pan-cancer cohorts, HTD2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated HTD2 data layer compared with 17 for mass-spec protein.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher HTD2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated HTD2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and UCEC show a favorable association.

CCRCC, GBM, and UCEC are the cancer types where HTD2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Tertile	All	0.993	0.706	<.001	33	view →
GBM	DFS	Median	All	0.245	0.463	.015	6	view →
UCEC	OS	Tertile	All	1.000	0.808	.030	4	view →
LUAD	OS	Tertile	II,III,IV	0.405	0.891	.039	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

HTD2–CCRCC (OS)

Open the CCRCC breakdown →